Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year - PubMed (original) (raw)
Clinical Trial
. 2005 Aug;28(8):1936-40.
doi: 10.2337/diacare.28.8.1936.
Affiliations
- PMID: 16043735
- DOI: 10.2337/diacare.28.8.1936
Clinical Trial
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
Bo Ahrén et al. Diabetes Care. 2005 Aug.
Abstract
Objective: To examine the effects of dipeptidyl peptidase-IV (DPP-4) inhibition on meal-related beta-cell function and insulin sensitivity over 52 weeks in type 2 diabetes.
Research design and methods: In a 12-week core study, placebo (n = 51) or vildagliptin (n = 56; 50 mg OD) was added to metformin treatment (1.5-3.0 mg/day). A 40-week extension followed in 71 patients. Meal tests were performed at 0, 12, 24, and 52 weeks; glucose, insulin, and C-peptide were evaluated.
Results: In subjects completing 52 weeks with participation in all meal tests (n = 57), HbA(1c) (A1C) decreased in the vildagliptin/metformin group (VM group, n = 31) but increased in the placebo/metformin group (PM group, n = 26; between-group difference -1.0 +/- 0.2%; P < 0.001; baseline of all subjects combined 7.7 +/- 0.1%). Also, fasting glucose decreased in the VM group but increased in the PM group (difference -0.9 +/- 0.3 mmol/l, P = 0.016; baseline 9.8 +/- 0.3 mmol/l). Insulin secretion (postmeal suprabasal area under the 0- to 30-min C-peptide curve divided by the 30-min increase in glucose) was increased in the VM group but was reduced in the PM group (difference +0.011 +/- 0.03 pmol/l 30 min/mmol/l, P = 0.018; baseline 0.036 +/- 0.02). Insulin sensitivity during meal ingestion (oral glucose insulin sensitivity) increased in the VM group but was not altered in the PM group (difference +27 +/- 4 ml x min(-1) x m(-2), P = 0.036; baseline 246 +/- 6). Insulin secretion related to insulin sensitivity (adaptation index) increased in the VM group but decreased in the PM group (difference +3.2 +/- 1.0, P = 0.040; baseline 9.1 +/- 0.5). The change in adaptation index correlated to the change in A1C (r = -0.39, P = 0.004).
Conclusions: This study presents evidence that DPP-4 inhibition by vildagliptin when added to metformin in type 2 diabetes over 52 weeks improves beta-cell function along with improved postmeal insulin sensitivity.
Similar articles
- The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. Utzschneider KM, et al. Diabetes Care. 2008 Jan;31(1):108-13. doi: 10.2337/dc07-1441. Epub 2007 Oct 1. Diabetes Care. 2008. PMID: 17909087 Clinical Trial. - Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B, Pacini G, Tura A, Foley JE, Schweizer A. Ahrén B, et al. Horm Metab Res. 2007 Nov;39(11):826-9. doi: 10.1055/s-2007-991172. Horm Metab Res. 2007. PMID: 17992639 Clinical Trial. - Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Dalla Man C, Bock G, Giesler PD, Serra DB, Ligueros Saylan M, Foley JE, Camilleri M, Toffolo G, Cobelli C, Rizza RA, Vella A. Dalla Man C, et al. Diabetes Care. 2009 Jan;32(1):14-8. doi: 10.2337/dc08-1512. Epub 2008 Oct 17. Diabetes Care. 2009. PMID: 18931099 Free PMC article. Clinical Trial. - Vildagliptin: a novel DPP-4 inhibitor with pancreatic islet enhancement activity for treatment of patients with type 2 diabetes.
Ristic S, Bates PC. Ristic S, et al. Drugs Today (Barc). 2006 Aug;42(8):519-31. doi: 10.1358/dot.2006.42.8.996570. Drugs Today (Barc). 2006. PMID: 16969429 Review. - Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.
Ahrén B. Ahrén B. Vasc Health Risk Manag. 2008;4(2):383-94. doi: 10.2147/vhrm.s1944. Vasc Health Risk Manag. 2008. PMID: 18561513 Free PMC article. Review.
Cited by
- Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
Croxtall JD, Keam SJ. Croxtall JD, et al. Drugs. 2008;68(16):2387-409. doi: 10.2165/0003495-200868160-00009. Drugs. 2008. PMID: 18973400 Review. - Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Bekiari E, Rizava C, Athanasiadou E, Papatheodorou K, Liakos A, Karagiannis T, Mainou M, Rika M, Boura P, Tsapas A. Bekiari E, et al. Endocrine. 2016 Jun;52(3):458-80. doi: 10.1007/s12020-015-0841-1. Epub 2015 Dec 29. Endocrine. 2016. PMID: 26714458 - Therapeutic Approaches for Preserving or Restoring Pancreatic β-Cell Function and Mass.
Jung KY, Kim KM, Lim S. Jung KY, et al. Diabetes Metab J. 2014 Dec;38(6):426-36. doi: 10.4093/dmj.2014.38.6.426. Diabetes Metab J. 2014. PMID: 25541605 Free PMC article. Review. - Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL. He YL. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. doi: 10.2165/11598080-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22339447 Review. - Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.
Foley JE, Jordan J. Foley JE, et al. Vasc Health Risk Manag. 2010 Aug 9;6:541-8. doi: 10.2147/vhrm.s10952. Vasc Health Risk Manag. 2010. PMID: 20730070 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous